Spleen response in transfusion-dependent thalassemic patients treated with ruxolitinib. (A) Change in spleen length from baseline below the left costal margin over time. (B) Percent change in spleen volume from baseline at week 30 measured by magnetic resonance imaging. Max, maximum; min, minimum.